ICER Report Finds GLP-1s Are Cost-Effective But Warns of Budget Strain

Two out of every 5 US adults live with obesity, and nearly 10% live with severe obesity, generating an estimated $173 billion in medical costs in 2019 alone. A commentary published in the Journal of Managed Care & Specialty Pharmacy examines what an Institute for Clinical and Economic Review (ICER) evidence report means for payers weighing coverage of glucagon-like peptide-1 (GLP-1) receptor agonists for obesity.¹

The authors conclude that the drugs deliver real clinical value, but that value comes paired with a budget impact problem that is already playing out in real time, including in the new Medicare GLP-1 Bridge Program.¹

What the ICER Report Found

ICER's evidence report evaluated the comparative effectiveness and value of injectable and oral semaglutide and tirzepatide for obesity treatment. The authors found the incremental cost-effectiveness ratios for injectable semaglutide, oral semaglutide, and tirzepatide, compared with lifestyle modification alone, to be $66,355, $75,456, and $57,779 per quality-adjusted life-year, respectively. By conventional cost-effectiveness standards, that places all 3 therapies within a reasonable value range.¹

The budget impact picture looks different. According to the commentary, treating even 1% of patients with semaglutide or tirzepatide would cross ICER's budget impact threshold of $880 million per year. With an estimated 1 in 8 US adults having already used a GLP-1 receptor agonist, that threshold is already well exceeded, and payers have reported widespread challenges managing the resulting costs. The authors compare the dynamic to previous cases in which ICER found high-value therapies, such as chimeric antigen receptor T-cell treatments, nonetheless created significant budget strain due to projected costs rather than any deficiency in clinical value.¹

The commentary cautions that ICER's projected long-term medical cost offsets may not hold up as expected. Real-world persistence with GLP-1 therapy for weight loss remains well below the rates observed in the clinical trials that informed ICER's models, and a recent meta-analysis found that patients who discontinue GLP-1 receptor agonists return to their prior weight within 1.5 years on average, with cardiometabolic measures also reverting toward baseline. Notably, weight regain was not affected by whether patients participated in a lifestyle management program while on therapy, though preliminary data suggest regain may be reduced when patients stay enrolled in such a program after stopping the drug.¹

Evidence on medical spending impact is similarly mixed. Cost-offset signals appear mainly among patients with both obesity and diabetes who receive high-potency injectable agents, while obesity-only populations often show medical spending increases instead. The authors note this distinction matters for coverage decisions, since patients with diabetes can already access GLP-1 receptor agonists through that indication even where obesity-specific coverage is restricted.¹

As of 2025, only 13 state Medicaid programs and roughly 1 in 5 employer-based plans cover GLP-1 receptor agonists for obesity, reflecting how restrictive coverage remains despite the drugs' demonstrated value. The authors recommend that managed care plans pair GLP-1 coverage with lifestyle management programs rather than covering the drug in isolation, avoid arbitrary duration limits on treatment in favor of targeted prior authorization, and explore alternative payment models such as subscription-style arrangements, value-based contracts tied to clinical outcomes, and population-level price-volume agreements to help manage cost while preserving access.¹

Medicare's Bridge Program as a Live Test Case

That exact tension between value and budget impact is now playing out through the Medicare GLP-1 Bridge Program, which launched July 1, 2026, and runs through December 31, 2027, offering eligible beneficiaries semaglutide (Wegovy), orforglipron (Foundayo), and tirzepatide (Zepbound KwikPen) at a fixed $50 copayment. The Centers for Medicare & Medicaid Services (CMS) is using the program specifically to evaluate whether GLP-1 weight loss drugs should become a permanent Medicare benefit—effectively the real-world budget test the ICER commentary describes.²

"The Medicare GLP-1 Bridge is a test program meant to help eligible Medicare patients get GLP-1 weight loss drugs," said Bryan Wheeler, PharmD, staff pharmacist at Dickson Medical Pharmacy, White Bluff Pharmacy, and Hilltop Pharmacy.² "Starting July 1, 2026, the Centers for Medicare & Medicaid Services will use this program to decide if these drugs should be a permanent part of Medicare."

For pharmacies, that test comes with real financial exposure. Reimbursement is structured around wholesale acquisition cost plus a dispensing fee, less the $50 copayment, but Wheeler noted that Wegovy alone exceeds $1300 per box, requiring pharmacies to carry substantial inventory of a temperature-sensitive product.²

Jay Bregman, founder and CEO of Andel, echoed the strain this places on independent pharmacies. "I just don't think that GLP-1s, or any expensive brand medication necessarily, are really great investments for local independent pharmacies," Bregman told Drug Topics®, pointing to limited refrigeration capacity and frequent backorders as compounding administrative burdens.³

Both pharmacists described a clinical opportunity alongside the financial risk. Wheeler pointed to medication therapy management and medication synchronization services as ways to build clinical revenue while supporting patients through counseling on pen technique, injection site rotation, sharps disposal, and management of gastrointestinal adverse effects.²

Bregman, meanwhile, emphasized why patients turn to pharmacists in the first place. "Particularly, when it comes to programs like Medicare, frankly, that generation is probably more apt to go into a pharmacy and speak to a human pharmacist," he said.³ "I think there's quite a lot that pharmacists can do to help people understand exactly what is the best deal for them."

Bregman also raised the same underlying question the ICER commentary poses about the program's future past its scheduled expiration at the end of 2027. "Either one of two things will happen," he said.³ "That will lead to actual savings, or it will just lead to increased demand for people to stay on the medication, and it will make it much more difficult for that subsidy to be rolled back in any way.”

Demand Keeps Climbing

The budget concerns ICER raises are compounded by how quickly GLP-1 use continues to grow. Nearly 8 of every 100 prescriptions filled in March 2026 were for GLP-1 receptor agonists, according to Truveta data drawn from electronic health records updated daily for more than 130 million patients in the US—the largest quarter-over-quarter percentage point increase in GLP-1 prescribing observed since tracking began in 2019.⁴

That growth is not confined to obesity and diabetes management. At the American Pharmacists Association 2026 Annual Meeting and Exposition, Emily Eddy, PharmD, BCACP, BC-ADM, CDCES, associate professor of pharmacy practice and director of clinical services at Ohio Northern University, described a drug class whose clinical footprint keeps expanding into heart failure, metabolic dysfunction-associated steatohepatitis, and obstructive sleep apnea, among other conditions.⁵

"This is a real game changer, and this has really changed the way we practice. We're now not just treating diabetes but underlying metabolic problems," Eddy said in her presentation.⁵ Every additional indication adds to the population of patients who may seek coverage—reinforcing exactly the budget dynamic the ICER commentary warns payers to plan for.

REFERENCES

1. Ramachandran S, Urick B, Thomas T. ICER report demonstrates both the value and challenges in financing of weight loss medications. J Manag Care Spec Pharm. 2026;32(6):753-757. doi:10.18553/jmcp.2026.32.6.753

2. Gallagher A, Wheeler B. FAQ: the Medicare GLP-1 bridge—what independent pharmacists need to know. Drug Topics. June 26, 2026. Accessed July 21, 2026. https://www.drugtopics.com/view/faq-the-medicare-glp-1-bridge-what-independent-pharmacists-need-to-know

3. Nowosielski B, Bregman J. Q&A: pharmacists are key guides for GLP-1 access in Medicare bridge program. Drug Topics. July 15, 2026. Accessed July 21, 2026. https://www.drugtopics.com/view/pharmacists-key-guides-for-glp-1-medicare-bridge-program

4. Gallagher A. GLP-1s made up eight of every 100 prescriptions filled in March 2026. Drug Topics. May 5, 2026. Accessed July 21, 2026. https://www.drugtopics.com/view/glp-1s-made-up-eight-of-every-100-prescriptions-filled-in-march-2026

5. Nowosielski B. GLP-1s taking over indications outside of diabetes and weight loss | APhA 2026. Drug Topics. April 6, 2026. Accessed July 21, 2026. https://www.drugtopics.com/view/glp-1s-taking-over-indications-outside-of-diabetes-and-weight-loss-apha-2026